p.84 抽出テキスト

pants in 29 Western prospective studies. Circulation 2007; 115: 450- 458. PMID: 17190864 128. Asia Pacific Cohort Studies Collaboration. Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation 2004; 110: 2678-2686. PMID: 15492305 129. Iso H, Naito Y, Sato S, et al. Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol 2001; 153: 490-499. PMID: 11226981 130. Satoh H, Nishino T, Tomita K, et al. Fasting triglyceride is a significant risk factor for coronary artery disease in middle-aged Japanese men ―Results From a 10-Year Cohort Study. Circ J 2006; 70: 227- 231. PMID: 16501284 131. Okamura T, Kokubo Y, Watanabe M, et al. A revised definition of the metabolic syndrome predicts coronary artery disease and ischemic stroke after adjusting for low density lipoprotein cholesterol in a 13year cohort study of Japanese: The Suita study. Atherosclerosis 2011; 217: 201-206. PMID: 21481396 132. Iso H, Imano H, Yamagishi K, et al. CIRCS Investigators. Fasting and non-fasting triglycerides and risk of ischemic cardiovascular disease in Japanese men and women: The Circulatory Risk in Communities Study (CIRCS). Atherosclerosis 2014; 237: 361-368. PMID: 25443874 133. Higashiyama A, Wakabayashi I, Okamura T, et al. The Risk of Fasting Triglycerides and its Related Indices for Ischemic Cardiovascular Diseases in Japanese Community Dwellers: the Suita Study. J Atheroscler Thromb 2021; 28: 1275-1288. PMID: 34053965 134. Nordestgaard BG, Langsted A, Mora S, et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points -a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J 2016; 37: 1944-1958. PMID: 27122601 135. Masuda D, Sugimoto T, Tsujii K, et al. Correlation of fasting serum apolipoprotein B-48 with coronary artery disease prevalence. Eur J Clin Invest 2012; 42: 992-999. PMID: 22587365 136. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/ AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 139: e1082-e1143. PMID: 30586774 137. Sone H, Tanaka S, Tanaka S, et al. Japan Diabetes Complications Study Group. Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: Subanalysis of the Japan Diabetes Complications Study (JDCS). J Clin Endocrinol Metab 2011; 96: 3448- 3456. PMID: 21865372 138. Colhoun HM, Betteridge DJ, Durrington PN, et al. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696. PMID: 15325833 139. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371: 117- 125. PMID: 18191683 140. Itoh H, Komuro I, Takeuchi M, et al. EMPATHY Investigators. Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy: Report of a Randomized Study. Diabetes Care 2018; 41: 1275-1284. PMID: 29626074 141. Itoh H, Komuro I, Takeuchi M, et al. EMPATHY Investigators. Achieving LDL cholesterol target levels <1.81 mmol/L may provide extra cardiovascular protection in patients at high risk: Exploratory analysis of the Standard Versus Intensive Statin Therapy for Patients with Hypercholesterolaemia and Diabetic Retinopathy study. Diabetes Obes Metab 2019; 21: 791-800. PMID: 30393955 142. スタチン不耐診療指針作成ワーキンググループ.スタチン不耐に関する診療指針2018.日本動脈硬化学会 2018. 143. Yamashita S, Matsuzawa Y. Where are we with probucol: A new life for an old drug? Atherosclerosis 2009; 207: 16-23. PMID: 19457483 144. Sugimoto K, Isobe K, Kawakami Y, et al. The relationship between non-HDL cholesterol and other lipid parameters in Japanese subjects. J Atheroscler Thromb 2005; 12: 107-110. PMID: 15942121 145. Shimano H, Arai H, Harada-Shiba M, et al. Proposed guidelines for hypertriglyceridemia in Japan with non-HDL cholesterol as the second target. J Atheroscler Thromb 2008; 15: 116-121. PMID: 18603817 146. Taguchi I, Iimuro S, Iwata H, et al. High-Dose Versus Low-Dose

Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial. Circulation 2018; 137: 1997-2009. PMID: 29735587 147. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and

safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278. PMID: 16214597 148. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-1681. PMID: 21067804 149. Cholesterol Treatment Trialists’ (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380: 581-590. PMID: 22607822 150. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015; 385: 1397-1405. PMID: 25579834 151. Nakamura H, Arakawa K, Itakura H, et al. MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006; 368: 1155-1163. PMID: 17011942 152. Itakura H, Kita T, Mabuchi H, et al. J-LIT Study Group. Relationship between coronary events and serum cholesterol during 10 years of low-dose simvastatin therapy: Long-term efficacy and safety in Japanese patients with hypercholesterolemia in the Japan Lipid Intervention Trial (J-LIT) Extension 10 Study, a prospective large-scale observational cohort study. Circ J 2008; 72: 1218-1224. PMID: 18654003 153. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009; 338: b2376. PMID: 19567909 154. Savarese G, Gotto AM Jr, Paolillo S, et al. Benefits of statins in elderly subjects without established cardiovascular disease: A meta-analysis. J Am Coll Cardiol 2013; 62: 2090-2099. PMID: 23954343 155. Silverman MG, Ference BA, Im K, et al. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA 2016; 316: 1289-1297. PMID: 27673306 156. Ouchi Y, Sasaki J, Arai H, et al. Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized, Controlled Trial. Circulation 2019; 140: 992-1003. PMID: 31434507 157. Zhan S, Tang M, Liu F, et al. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. Cochrane Database Syst Rev 2018: CD012502. PMID: 30480766 158. Schmidt AF, Carter JL, Pearce LS, et al. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2020: CD011748. PMID: 33078867 159. Sniderman AD, Williams K, Contois JH, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 2011; 4: 337-345. PMID: 21487090 160. Langlois MR, Nordestgaard BG, Langsted A, et al. European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. Clin Chem Lab Med 2020; 58: 496-517. PMID: 31855562 161. Marston NA, Giugliano RP, Im K, et al. Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials. Circulation 2019; 140: 1308-1317. PMID: 31530008 162. Keech A, Simes RJ, Barter P, et al. FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-1861. PMID: 16310551 163. Ginsberg HN, Elam MB, et al. ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563-1574. PMID: 20228404 164. Jakob T, Nordmann AJ, Schandelmaier S, et al. Fibrates for primary prevention of cardiovascular disease events. Cochrane Database Syst Rev 2016: CD009753. PMID: 27849333 165. Scott R, O’Brien R, Fulcher G, et al. Fenofibrate Intervention and

Event Lowering in Diabetes (FIELD) Study Investigators. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic